中文

博雅生物 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-25
ItemAmountY/Y
Revenue¥0.32B-40.1%
Gross profit¥0.15B
Operating income¥0.04B
Net income¥0.03B-78.4%
Gross margin46.3%Net margin 9.4%
Revenue Q/Q-45.1%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.17B53.7%
R&D¥0.00B1.3%
SG&A¥0.12B38.7%
Tax & other¥0.01B2.2%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

*ST三六五利亚德三诺生物富春股份海峡创新ST长方同有科技聚飞光电云意电气裕兴股份远方信息慈星股份

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies